Abstract: New uses of Cyclo-HisPro (CHP) or a salt thereof for lowering blood pressure are disclosed. More specifically, the present invention relates to a pharmaceutical composition for lowering blood pressure, containing CHP or a salt thereof, and a functional health food composition containing CHP or a salt thereof; a method for lowering blood pressure using CHP or a salt thereof; a use of CHP or a salt thereof in the manufacture of antihypertensive agents; a pharmaceutical composition or a functional health food, for preventing or treating hypertension or complications thereof, containing CHP or a salt thereof; a method for preventing or treating hypertension or complications thereof by using CHP or a salt thereof; and a use of CHP or a salt thereof in the manufacture of a medicament for preventing or treating hypertension or complications thereof.

Abstract: New uses of a novel PPAR activity modulator for the prevention, amelioration or treatment of degenerative brain diseases are disclosed. More specifically, disclosed are a composition for the prevention, amelioration or treatment of degenerative brain diseases by using a PPAR active agent that binds to and activates all subtypes of PPAR of PPAR, and a composition for enhancing learning ability, improving memory, or ameliorating cognitive decline. Also, provided are a method for the prevention, amelioration or treatment of degenerative brain diseases by using the novel PPAR active agent, and a method for enhancing learning ability, improving memory or ameliorating cognitive decline.

Abstract: A cyclo(His-Pro)(CHP) is useful for preventing, alleviating or treating peritoneal fibrosis. A pharmaceutical composition for preventing or treating peritoneal fibrosis, a dietary supplement composition for preventing or alleviating peritoneal fibrosis, and a peritoneal dialysis solution, which all contain CHP is disclosed. Also disclosed are a method for preventing or treating peritoneal fibrosis by using CHP, a peritoneal dialysis method using CHP, a use of CHP during the preparation of a pharmaceutical composition for preventing or treating peritoneal fibrosis, and/or a use of CHP in the preparation of a peritoneal dialysis solution.

Abstract: The present invention provides a pharmaceutical composition for use in preventing or treating metabolic diseases comprising a novel pan-PPAR agonist compound or a salt thereof as an active ingredient. As the pan-PPAR agonist, the compound or the salt thereof may be useful in pharmaceutical compositions for preventing or treating metabolic diseases such as obesity, diabetes, fatty liver diseases, dyslipidemia, cardiovascular diseases, and/or metabolic syndrome, and in food or feed compositions for improving metabolic health.

Abstract: A composition for preventing and/or treating pancreatitis and a method of prevention and/or treatment of pancreatitis are disclosed. The composition include an aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient. Also disclosed is a use of the aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, in manufacturing a medicament for preventing and/or treating pancreatitis or for treating one or more symptoms of pancreatitis in a patient. The method of prevention and/or treatment of pancreatitis includes administering the aryl ethene compound, an isomer, a pharmaceutically acceptable salt thereof, or a solvate thereof, in an effective amount to a subject in need thereof.

Abstract: A composition for preventing, ameliorating or treating obesity and diabetes and its uses are disclosed. The composition includes zinc gluconate and cyclo-hispro (CHP) as active ingredients. More specifically, the composition includes the type of zinc salts and/or the content ratio of zinc components optimized for surprisingly significantly improved anti-obesity and anti-diabetic effects. A method of preventing, ameliorating or treating obesity and diabetes using the composition is also disclosed.

Abstract: A method and composition for treating and/or preventing ?-cell dysfunction and/or protecting impaired ?-cells are disclosed. The method includes administering an effective amount of cyclo (his-pro) (CHP), alone or with zinc, to a subject. The composition contains an effective amount of cyclo (his-pro) (CHP) as an active ingredient. The composition may further contain zinc and/or other antidiabetic agent, or can be administered in combination with zinc and/or other antidiabetic agent.

Abstract: A new use of a cyclo(His-Pro) is disclosed. In particular, a method for treating fibrosis and/or inflammation which includes administering an effective amount of an isolated cyclo (His-Pro) to a subject in need thereof is disclosed.

Abstract: A composition containing cyclo-hispro (CHP) and its use in preventing, alleviating, or treating bone loss diseases are disclosed. The composition contains CHP or a CHP-containing prostate extract.

Abstract: Novel PEG modified cyclic dipeptide compounds are disclosed. The modified cyclic dipeptide compounds contain a cyclic dipeptide and a biocompatible polymer attached to the cyclic dipeptide. The cyclic dipeptide may be proline-containing, hydroxyproline-, or histidine-containing cyclic dipeptide. In one embodiment, the cyclic dipeptide is a cyclo (-his-pro).

Abstract: A composition for preventing and/or treating cytokine release syndrome and a method of prevention and/or treatment of cytokine release syndrome are disclosed. The composition includes an aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient. The method includes administering the aryl ethene compound, an isomer, a pharmaceutically acceptable salt thereof, or a solvate thereof, in an effective amount to a subject in need thereof. The cytokine release syndrome may be caused by virulent infection. The administration of the compound reduces the pre-inflammatory cytokine levels in the subject.

Abstract: A composition for preventing and/or treating cytokine release syndrome and a method of prevention and/or treatment of cytokine release syndrome are disclosed. The composition includes an aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient. The method includes administering the aryl ethene compound, an isomer, a pharmaceutically acceptable salt thereof, or a solvate thereof, in an effective amount to a subject in need thereof. The cytokine release syndrome may be caused by virulent infection. The administration of the compound reduces the pre-inflammatory cytokine levels in the subject.

Abstract: New uses of Cyclo-HisPro (CHP) or a salt thereof for lowering blood pressure are disclosed. More specifically, the present invention relates to a pharmaceutical composition for lowering blood pressure, containing CHP or a salt thereof, and a functional health food composition containing CHP or a salt thereof; a method for lowering blood pressure using CHP or a salt thereof; a use of CHP or a salt thereof in the manufacture of antihypertensive agents; a pharmaceutical composition or a functional health food, for preventing or treating hypertension or complications thereof, containing CHP or a salt thereof; a method for preventing or treating hypertension or complications thereof by using CHP or a salt thereof; and a use of CHP or a salt thereof in the manufacture of a medicament for preventing or treating hypertension or complications thereof.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating diabetes, comprising, as active ingredients: (a) a zinc salt, comprising a zinc cation and anion, and cyclo-hispro, or a pharmaceutically acceptable salt thereof; and (b) an antidiabetic drug (particularly, an insulin sensitizer, an insulin sensitizer, a sodium-glucose co-transporter (a sodium-glucose co-transporter 2 (SGLT2) inhibitor), or a DPP-4 inhibitor).

Abstract: A composition for preventing and/or treating pancreatitis and a method of prevention and/or treatment of pancreatitis are disclosed. The composition include an aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient. Also disclosed is a use of the aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, in manufacturing a medicament for preventing and/or treating pancreatitis or for treating one or more symptoms of pancreatitis in a patient. The method of prevention and/or treatment of pancreatitis includes administering the aryl ethene compound, an isomer, a pharmaceutically acceptable salt thereof, or a solvate thereof, in an effective amount to a subject in need thereof.

Abstract: A composition for preventing and/or treating pancreatitis and a method of prevention and/or treatment of pancreatitis are disclosed. The composition include an aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient. The method includes administering the aryl ethene compound, an isomer, a pharmaceutically acceptable salt thereof, or a solvate thereof, in an effective amount to a subject in need thereof.

Abstract: A use of a cyclo(his-pro) (CHP) in combination with parathyroid hormone (PTH) and compositions containing the CHP in combination with PTH is disclosed. The combination of CHP and PTH is useful for preventing, improving, or treating a bone loss-related disease. Therefore, a method for treating, preventing, or improving bone loss-related disease in a subject, which includes administering the CHP in combination with PTH is disclosed. The PTH and CHP may be administered to the subject simultaneously, separately, or sequentially.

Abstract: A Cyclo (his-pro) (CHP) is useful for preventing, ameliorating, or treating fibrosis. A pharmaceutical composition containing CHP may be used for preventing or treating fibrosis. A health functional food composition containing CHP may be used for preventing or ameliorating fibrosis. An antifibrotic composition, a method of preventing, ameliorating, or treating fibrosis by using CHP, and/or a use of CHP in the manufacture of the pharmaceutical composition for preventing or treating fibrosis are disclosed.

Abstract: A new use of a cyclo(His-Pro) is disclosed. In particular, a method for treating fibrosis and/or inflammation which includes administering an effective amount of an isolated cyclo (His-Pro) to a subject in need thereof is disclosed.

Abstract: A cyclo(His-Pro)(CHP) is useful for preventing, alleviating or treating peritoneal fibrosis. A pharmaceutical composition for preventing or treating peritoneal fibrosis, a dietary supplement composition for preventing or alleviating peritoneal fibrosis, and a peritoneal dialysis solution, which all contain CHP is disclosed. Also disclosed are a method for preventing or treating peritoneal fibrosis by using CHP, a peritoneal dialysis method using CHP, a use of CHP during the preparation of a pharmaceutical composition for preventing or treating peritoneal fibrosis, and/or a use of CHP in the preparation of a peritoneal dialysis solution.